CUPRIMINE - Typical cost for a 30 day supply: $39,800. Treats Wilson’s Disease, the buildup of copper in liver and other organs; Cystinuria, which causes kidney stones; and rheumatoid arthritis.

ORKAMBI - Typical cost for a 30-day supply: $44,200. Treats cystic fibrosis patients who have a specific gene mutation, won FDA approval last month to be given to patients as young as 6 years old. It had previously been limited to those age 12 and older.

FIRAZYR - Typical cost for a 30-day supply: $35,800. Treats Hereditary Angioedema, a blood disorder. Patients with HAE take Cyrinze to prevent an attack, and Firazyr once symptoms of one occur. They’re both owned by the pharmaceutical firm Shire.

HP ACTHAR - Typical cost for a 30-day supply: $51,600. Treats Systemic Lupus Erythematosus; Proteinuria in Nephrotic Syndrome, too much protein in urine; dermatomyositis and polymyositis, bone joint and muscle disorders; rheumatoid and psoriatic arthritis; multiple sclerosis; infantile spasms, a catastrophic form of childhood epilepsy; sarcoidosis, an inflammation disease; and several ophthalmic conditions.

DAKLINZA - Typical cost for a 30-day supply: $54,300. Treats Hepatitis C. Approved by the Food and Drug Administration last summer, Daklinza can cure 90 percent of patients who haven’t been previously treated and 86 percent of those who had failed a previous treatment. It’s specifically aimed at patients with hep C genotype 3, which is considered the most difficult to treat.

OLYSIO - Typical cost for a 30-day supply: $44,800. Treats Hepatitis C. Approved in November 2014, Johnson & Johnson’s Oylsio was one of the first drugs with high hepatitis C cure rates, but it has since lost market share to competitors such as Sovaldi. More than 3 million Americans, including 5 percent of veterans, have hepatitis C, a potentially deadly liver disease

CINRYZE - Typical cost for a 30-day supply: $72,100. Treats Hereditary Angioedema, a blood disorder. Cinryze is the only FDA-approved treatment for HAE, which causes potentially life-threatening extreme swelling to extremities that can last for days. The drug is administered via injection either in a doctor’s office or at home.

VIEKIRA PAK - Typical cost for 30-day supply: $34,600. Treats Hepatitis. Co-owned by AbbVie, the FDA in April expanded the type of hepatitis patients who could be treated by Viekira Pak. The drug stops the hepatitis C virus from multiplying.

HARVONI - Typical cost for 30-day supply: $79,200. Treats Hepatitis C. Harvoni is made by Gilead Pharmaceuticals and boasts cure rates of more than 95 percent, more than twice that of competitors. Prices have come down slightly this year as new drugs enter the market.

SOVALDI - Typical cost for 30-day supply: $81,000. Treats Hepatitis C. Drug-maker Gilead Pharmaceuticals claims that the price of the pills, which boast an extraordinary cure rate, is justified because of the money spent developing them. When it launched in 2014, Sovaldi quickly became the fastest-selling drug in history